ArticleCA: a cancer journal for clinicians
Clinical trials in the era of personalized oncology.
Article in CA: a cancer journal for clinicians. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Shifting, overlapping and expanding use of "precision oncology" terminology: a retrospective literature analysis.BMJ open · 2020Pooled it
- Examining external control arms in oncology: A scoping review of applications to date.Cancer medicine · 2024Article
- Application of Nanoparticles in Cancer Treatment: A Concise Review.Nanomaterials (Basel, Switzerland) · 2023Review
- The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update.Frontiers in immunology · 2023Review
- New challenges in the use of nanomedicine in cancer therapy.Bioengineered · 2022Article
- Integrated analysis identifies a novel lncRNA prognostic signature associated with aerobic glycolysis and hub pathways in breast cancer.Cancer medicine · 2021Article
- Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer.Molecules (Basel, Switzerland) · 2021Review
- The Effect of Quercetin Nanosuspension on Prostate Cancer Cell Line LNCaP via Hedgehog Signaling Pathway.Reports of biochemistry & molecular biology · 2021Article
- Clinical potential of mass spectrometry-based proteogenomics.Nature reviews. Clinical oncology · 2019Review
- Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology.JCO clinical cancer informatics · 2018Article
- [Big data in imaging].Zeitschrift fur Rheumatologie · 2018Review
- Recent advances in "smart" delivery systems for extended drug release in cancer therapy.International journal of nanomedicine · 2018Review
- Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer.Cellular and molecular gastroenterology and hepatology · 2018Article
- Increased Jab1/COPS5 is associated with therapeutic response and adverse outcome in lung cancer and breast cancer patients.Oncotarget · 2017Article
- Managing Expectations in the Transition to Proof of Concept Studies.Reviews on recent clinical trials · 2017Review
- Concordance of folate receptor-α expression between biopsy, primary tumor and metastasis in breast cancer and lung cancer patients.Oncotarget · 2016Article
- Clinical trial designs incorporating predictive biomarkers.Cancer treatment reviews · 2016Review
- Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.Clinical and translational science · 2016Article
- The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies.International journal of biological sciences · 2016Review
- Review of Developments in Electronic, Clinical Data Collection, and Documentation Systems over the Last Decade - Are We Ready for Big Data in Routine Health Care?Frontiers in oncology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The rapid pace of discoveries in tumor biology, imaging technology, and human genetics hold promise for an era of personalized oncology care. The successful development of a handful of new targeted agents has generated much hope and hype about the delivery of safer and more effective new treatments for cancer. The design and conduct of clinical trials has not yet adjusted to a new era of personalized oncology and so we are more in transition to that era than in it. With the development of treatments for breast cancer as a model, we review the approaches to clinical trials and the development of novel therapeutics in the prior era of population oncology, the current transitional era, and the future era of personalized oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.